Compare SATL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SATL | CTNM |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.2M | 550.7M |
| IPO Year | 2021 | 2024 |
| Metric | SATL | CTNM |
|---|---|---|
| Price | $4.66 | $16.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 5.5M | 540.4K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.94 | 0.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,707,000.00 | N/A |
| Revenue This Year | $88.89 | N/A |
| Revenue Next Year | $56.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.58 | N/A |
| 52 Week Low | $1.26 | $8.60 |
| 52 Week High | $12.00 | $17.51 |
| Indicator | SATL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 57.09 |
| Support Level | $4.52 | $13.65 |
| Resistance Level | $6.09 | $17.04 |
| Average True Range (ATR) | 0.33 | 0.97 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 2.13 | 72.87 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.